Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Joins Canada's National Access Project

NEW YORK (GenomeWeb) – Illumina has joined Canada's National Access Project consortium. 

Illumina's technology will be used to sequence DNA collected through the project, which is managed by the Personalized Medicine Initiative. Testing for the project is being carried out by Vancouver, British Columbia-based molecular diagnostics firm Contextual Genomics. 

The National Access Project's goal is to make genomic testing a standard in cancer care and to enable a personalized medicine approach to treating the disease. 

Through the project about 2,000 patients will receive a 90-mutation cancer genomic test for free. The first phase of the project is currently underway and is retrospectively mapping tumors to identify mutations for about 500 patients. Each identified mutation is actionable with current therapies or therapies in Phase III studies. 

In the second phase, the project will be expanded to include about 1,500 patients to prospectively evaluate and match specific tumor types with about 40 therapy options. 

Funding and technical assistance for the project is being provided by Illumina, AstraZeneca, Pfizer, Sanofi, and others.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.